Great Lakes Advisors LLC Sells 46,132 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Great Lakes Advisors LLC lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 20.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 178,477 shares of the biopharmaceutical company’s stock after selling 46,132 shares during the period. Great Lakes Advisors LLC’s holdings in Amicus Therapeutics were worth $1,681,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of FOLD. Los Angeles Capital Management LLC increased its holdings in Amicus Therapeutics by 46.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,484 shares during the period. Tokio Marine Asset Management Co. Ltd. bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $113,000. Wrapmanager Inc. bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $220,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Amicus Therapeutics by 51.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock worth $2,381,000 after acquiring an additional 75,807 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $834,000.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $8.90 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $8.55 and a 52-week high of $12.65. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -49.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a fifty day moving average of $9.38 and a 200-day moving average of $10.15. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on FOLD shares. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.